Endpoints News

Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm’s label expansion in rare form of obesity

Published

3 weeks ago

on

March 20, 2026

By

Temp User

Plus, news about Gilead, Assembly Biosciences and Pfizer:

📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a failed confirmatory study for its two exon-skipping …

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

The old and New Edition cast comes together to perform
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version